Physician profile
Kerry D Morgan
NPI 1194749150
$8,959.61
in general payments reported to CMS, 2019-2025
38 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $718 · 2021: $1,558 · 2022: $1,624 · 2023: $1,551 · 2024: $1,367 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,999 · Travel and Lodging: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,999.23 |
| Travel and Lodging | $351.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,064.28 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $785.01 | 2019-2025 | Lifevest |
| Medtronic, INC. | $712.95 | 2021-2025 | Symplicity G3, Onyx Frontier, Hawkone |
| Biotronik INC. | $608.73 | 2019-2025 | Solia, Amvia Edge, Selectra |
| Abiomed | $606.09 | 2019-2025 | Impella |
| Merck Sharp & Dohme LLC | $431.78 | 2021-2025 | Verquvo |
| Amgen INC. | $378.33 | 2020-2025 | Repatha, Repatha |
| Cvrx, INC. | $356.70 | 2023-2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $355.60 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $321.68 | 2019-2025 | Watchman Flx, Enroute Transcarotid Stent, Wolverine Coronary Cutting Balloon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.60 | 2020-2024 | Jardiance |
| Amarin Pharma, INC. | $250.06 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $224.17 | 2020-2025 | |
| Esperion Therapeutics, INC. | $221.53 | 2020-2024 | Nexlizet, Nexletol |
| Abbott Laboratories | $220.23 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $217.90 | 2019-2025 | |
| Daiichi Sankyo INC. | $207.70 | 2021-2022 | |
| Veryan Medical Incorporated | $188.64 | 2021-2022 | |
| Penumbra, INC. | $184.45 | 2023-2025 | Smart Coil, Indigo System, Penumbra System |
| Novo Nordisk INC | $169.45 | 2023-2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $167.15 | 2019-2025 | Camzyos, Eliquis |
| Opsens INC. | $118.35 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $104.82 | 2023-2024 | Inpefa |
| Bard Peripheral Vascular, INC. | $102.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $100.15 | 2019-2021 | |
| Avinger INC. | $97.79 | 2022 | |
| Daxor Corporation | $79.24 | 2022-2023 | Bva-100 |
| Philips North America LLC | $75.58 | 2020-2022 | |
| Bardy Diagnostics, INC. | $60.00 | 2021-2022 | |
| Cardiva Medical, INC. | $45.80 | 2019-2023 | Cardiva Vascade 6/7f Vcs |
| Medtronic Vascular, INC. | $36.95 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $34.47 | 2019-2023 | Evkeeza |
| Edwards Lifesciences Corporation | $29.82 | 2022 | |
| Baxter Healthcare | $27.85 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Irhythm Technologies, INC. | $20.76 | 2022 | |
| Chiesi USA, INC. | $19.24 | 2023 | Kengreal |
| Terumo Medical Corporation | $14.76 | 2019 | |
| Vifor Pharma, INC. | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.